» Articles » PMID: 36551871

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer

Overview
Journal Biomedicines
Date 2022 Dec 23
PMID 36551871
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, sensitive and specific methods for the detection and prognosis of early stage PCa are lacking. To establish the diagnosis and further identify an appropriate treatment strategy, prostate specific antigen (PSA) blood test followed by tissue biopsy have to be performed. The combination of tests is justified by the lack of a highly sensitive, specific, and safe single test. Tissue biopsy is specific but invasive and may have severe side effects, and therefore is inappropriate for screening of the disease. At the same time, the PSA blood test, which is conventionally used for PCa screening, has low specificity and may be elevated in the case of noncancerous prostate tumors and inflammatory conditions, including benign prostatic hyperplasia and prostatitis. Thus, diverse techniques of liquid biopsy have been investigated to supplement or replace the existing tests of prostate cancer early diagnosis and prognostics. Here, we provide a review on the advances in diagnosis and prognostics of non-metastatic prostate cancer by means of various biomarkers extracted via liquid biopsy, including circulating tumor cells, exosomal miRNAs, and circulating DNAs.

Citing Articles

Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.

Hamid Y, Rabbani R, Afsara R, Nowrin S, Ghose A, Papadopoulos V Int J Mol Sci. 2025; 26(2).

PMID: 39859516 PMC: 11765602. DOI: 10.3390/ijms26020802.


Knowledge mapping of exosomes in prostate cancer from 2003 to 2022: a bibliometric analysis.

Li Y, Ma L, Chen H, Jin Z, Yang W, Qiao Y Discov Oncol. 2024; 15(1):307.

PMID: 39048891 PMC: 11269540. DOI: 10.1007/s12672-024-01183-x.


Liquid biopsy to personalize treatment for metastatic prostate cancer.

Lopez-Valcarcel M, Lopez-Campos F, Zafra J, Cienfuegos I, Ferri M, Barrado M Am J Transl Res. 2024; 16(5):1531-1549.

PMID: 38883349 PMC: 11170619. DOI: 10.62347/DICU9510.


Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer.

Chen T, Mihalopoulos M, Zuluaga L, Rich J, Ganta T, Mehrazin R Int J Mol Sci. 2023; 24(19).

PMID: 37834162 PMC: 10573190. DOI: 10.3390/ijms241914713.


Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.

Huang H, Chen C, Chang K, Lee M, Lee C, Chao Y J Transl Med. 2023; 21(1):714.

PMID: 37821919 PMC: 10566053. DOI: 10.1186/s12967-023-04424-9.


References
1.
Joosse S, Muller V, Steinbach B, Pantel K, Schwarzenbach H . Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br J Cancer. 2014; 111(5):909-17. PMC: 4150270. DOI: 10.1038/bjc.2014.360. View

2.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

3.
Campbell D, Lund M, Nocon A, Cozzi P, Frydenberg M, de Souza P . Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One. 2018; 13(4):e0196017. PMC: 5908171. DOI: 10.1371/journal.pone.0196017. View

4.
Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

5.
Brikun I, Nusskern D, Gillen D, Lynn A, Murtagh D, Feczko J . A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients. Biomark Res. 2014; 2(1):25. PMC: 4278343. DOI: 10.1186/s40364-014-0025-9. View